U.S. Healthtech Stock News

Why CoStar's latest guidance and capital plan matter for shareholders CoStar Group (CSGP) has put fresh 2026 guidance on the table, pairing revenue and earnings targets with a new US$1.5b share repurchase plan and lower planned spending on Homes.com. For 2026, the company is guiding to revenue between US$3.78b and US$3.82b, and net income of US$175m to US$215m, or US$0.42 to US$0.52 per diluted share based on 416 million shares. Management also outlined an expansion in Adjusted EBITDA...

With no single headline event driving attention today, Packaging Corporation of America (PKG) is back on investors’ radar as they reassess the stock’s recent performance and its core business in containerboard and paper. See our latest analysis for Packaging Corporation of America. After a recent 5.1% 1 month share price return, Packaging Corporation of America now trades at US$206.81, while the 1 year total shareholder return of 7.2% decline contrasts with a 68.6% gain over three years...

In recent weeks, ConocoPhillips has come under the spotlight as U.S. policy discussions about reopening Venezuela’s oil sector revived its long-running arbitration claims of about US$10–12 billion for past asset nationalizations. What makes this especially important is the prospect that ConocoPhillips could convert part of those claims into low-cost equity stakes and cash recoveries, potentially reshaping its portfolio without drawing heavily on existing cash flow. With that backdrop, we'll...

Kinder Morgan recently attracted attention for its steady cash generation, income-focused profile, and upcoming earnings report, alongside positive revisions to earnings and revenue estimates. At the same time, insider share sales by a senior executive and a broader pattern of insider selling have added another layer for investors to interpret. With earnings expectations being revised upward, we’ll examine how this improving outlook fits into Kinder Morgan’s longer-term investment...

In early January 2026, Carpenter Technology drew increased attention after commentary emphasized its role supplying high-performance alloys to aerospace, defense, and medical customers amid rising demand and multi-year industrial trends such as re-arming and reshoring manufacturing. At the same time, the company scheduled a January 29, 2026 webcast to review its second-quarter fiscal 2026 results, giving investors a near-term window into how these demand drivers are reflected in recent...

If you have been wondering whether Energy Transfer is still good value at around US$16.52 a unit, you are not alone. Many income focused investors are asking the same question. The unit price has been relatively steady in the short term, with a 0.2% move over 7 days and a 1.7% decline over 30 days. The longer term picture includes a 0.4% decline year to date, a 9.8% decline over 1 year, a 69.2% return over 3 years and a 239.6% return over 5 years. Recent moves in Energy Transfer units come...

Roper Technologies has already announced that it released its fourth‑quarter 2025 results on January 27, 2026, and held a conference call to discuss performance and outlook. Ahead of and around this earnings release, mixed analyst opinions and a rise in short interest have sharpened focus on how investors view Roper’s near‑term prospects. We’ll now explore how these diverging analyst views and shifting short interest may influence Roper Technologies’ existing investment narrative. This...

What Aon’s Recent Share Performance Signals for Investors Aon (NYSE:AON) has drawn fresh attention after a mixed run in its share performance, with a small gain over the past month and a modest decline across the past 3 months that is testing investor conviction. At a recent close of US$349.92, the stock sits close to flat over the past year. Over the same period, the company reports annual revenue of US$17.0b and net income of US$2.7b, figures that help frame how the current valuation is...

Investors may be wondering if Essential Properties Realty Trust is good value at around US$29.91, or if the recent price leaves little upside on the table. The stock has had mixed returns, with a 0.8% gain over the last 7 days but a 3.5% decline over 30 days. Over longer periods it has returned 41.3% over 3 years and 80.4% over 5 years. Recent attention on Essential Properties Realty Trust has focused on its position in the net lease real estate space and how investors view income focused...

CareDx’s new ImmuneScape collaboration with 10x Genomics (TXG) is putting fresh attention on 10x’s spatial and single cell platforms, as investors weigh what this large scale transplant research effort could mean for the stock. See our latest analysis for 10x Genomics. The ImmuneScape announcement lands on top of strong recent momentum, with a 7 day share price return of 22.56% and a 90 day share price return of 70.71%. However, the 5 year total shareholder return is still down 88.61%,...

Why OceanFirst Financial is on investors’ radar OceanFirst Financial (OCFC) has drawn attention after recent share price pressure, with the stock showing negative returns over the past week, month, and past 3 months, prompting closer scrutiny of its current valuation. See our latest analysis for OceanFirst Financial. While the share price is down 11.5% over the past month and 3.3% year to date, the 1 year total shareholder return of 0.3% and 5 year total shareholder return of 5.2% suggest...

WD-40 (WDFC) is back in focus this week as the company prepares to report earnings on Thursday after the bell, a key moment following last quarter’s mixed revenue and EBITDA outcome. See our latest analysis for WD-40. At a share price of $198.98, WD-40 has seen a 6.11% 1 month share price return and a 3.25% 3 month share price return, while its 1 year total shareholder return of 15.14% decline contrasts with a 23.31% gain over three years. This suggests that shorter term momentum has softened...

Apogee Enterprises Q3 2026 Earnings Snapshot Apogee Enterprises (APOG) has just turned in another data point in a volatile stretch, with recent quarterly revenue sitting at about US$358.2 million and basic EPS of roughly US$1.10, against a trailing twelve month picture that shows total revenue of about US$1.39 billion and EPS of roughly US$2.07. Over the last few reported quarters, the company has seen revenue move from about US$331.5 million and EPS of roughly US$1.42 in early 2025 to the...

If you are wondering whether Trade Desk is attractively priced or just a story stock at this point, starting with a clear look at value can help you set expectations before making any decisions. The shares last closed at US$38.65, with a 1.8% gain over the past 7 days, a 1.8% decline over 30 days, a 2.6% return year to date, and a 68.2% decline over the past year. These moves may have changed how investors see both its potential and its risks. Recent attention on Trade Desk has focused on...

In the past few days, Encore Capital Group reported strong third-quarter 2025 results, with earnings per share and revenue both surpassing forecasts on the back of higher-than-expected collections. This outperformance has reinforced confidence in Encore’s ability to convert its large portfolio of purchased debt into cash flows more efficiently than anticipated. We’ll now examine how Encore’s better-than-forecast collections and earnings shape the company’s existing investment narrative and...

If you are wondering whether Mid-America Apartment Communities is attractively priced today, this article walks through what the current share price might be implying about value. The stock closed at US$134.98, with a 7 day return of 2.8% decline, a 30 day return of 3.0% and a year to date return of 3.0% decline, while the 1 year return sits at 5.8% decline and the 3 year return at 5.1% decline, compared with a 5 year return of 27.0%. Recent price moves have come alongside ongoing investor...

KBR (KBR) is back in focus after securing two sizable U.S. government awards, including a seat on the Missile Defense Agency’s SHIELD contract with a US$151b ceiling and a US$350m technical services deal with USGS. See our latest analysis for KBR. These contract wins come after a mixed stretch for the stock, with a 7 day share price return of 5.1% but a 1 year total shareholder return decline of 25.5%, suggesting recent momentum is picking up after a tougher year. If KBR’s government work has...

Why Vita Coco Company (COCO) is on investors’ radar Vita Coco Company (COCO) has drawn attention after a period of strong longer term share performance, with the stock showing a 59.6% 1 year total return and a very large 3 year gain. At a last close of US$54.22, the coconut water and functional beverage producer sits above its month return of 1.2% and past 3 months return of 26.8%, which is prompting closer inspection of the business. See our latest analysis for Vita Coco Company. That 26.8%...

GEO Group (GEO) has drawn fresh attention after recent trading left the shares with a one-month return of about 4% and a roughly 11% decline over the past three months, prompting closer scrutiny of its current valuation. See our latest analysis for GEO Group. At a share price of $16.19, GEO Group’s 1-year total shareholder return of about 48% decline contrasts with a 3-year total shareholder return of roughly 47% and a 5-year total shareholder return near 91%. This suggests that longer term...

Why American Bitcoin is on investors’ radar American Bitcoin (ABTC) has drawn attention after recent trading, with the share price at US$1.91 and value metrics such as a value score of 4 and an intrinsic discount of 36.0% now in focus. See our latest analysis for American Bitcoin. Recent trading has been choppy, with a 12.35% 7 day share price return sitting alongside a 5.45% 30 day decline and a much steeper 70.84% 90 day share price pullback. This suggests momentum has been fading despite...

On 6 January 2026, Zai Lab announced that China’s National Medical Products Administration approved a supplemental New Drug Application for AUGTYRO (repotrectinib) to treat adult patients with NTRK gene fusion solid tumors that are locally advanced or metastatic, or unsuitable for surgery, including those previously treated with TRK TKIs. This decision makes AUGTYRO the first therapy in China approved across both TRK TKI-naive and TRK TKI-pretreated solid tumor patients, potentially...

Event context and recent performance snapshot A. O. Smith (AOS) stock has drawn fresh attention after recent trading left the shares around $67.12, with returns roughly flat over the past month and a modest decline over the past 3 months. See our latest analysis for A. O. Smith. Zooming out, the 1 year total shareholder return is roughly flat at a 0.26% decline. The 3 and 5 year total shareholder returns of 13.28% and 25.95% suggest longer term holders have still seen gains even as recent...

AAR Corp. (AIR) has reported results for Q2 2026, with revenue of US$795.3 million and basic EPS of US$0.92, alongside trailing twelve month EPS of US$2.59 and net income of US$94.1 million. The company’s revenue has increased from US$686.1 million in Q2 2025 to US$795.3 million in Q2 2026, while quarterly EPS has moved from a loss of US$0.87 to a profit of US$0.92. This represents a very large year-over-year earnings improvement that feeds into forecasts calling for about 34.7% annual...

GSK and Ionis Pharmaceuticals recently reported that their experimental hepatitis B therapy bepirovirsen met primary endpoints in two Phase 3 trials, achieving a statistically significant and clinically meaningful functional cure rate and supporting planned global regulatory filings. The success of bepirovirsen not only adds a potentially first-in-class hepatitis B treatment to Ionis’s RNA-based portfolio, it also activates up to US$150,000,000 in potential milestones plus tiered royalties...